Novel hormonal delivery method using the ink-jet technology: Application to pulmonary insulin therapies

Diabetes Technology and Therapeutics

Volumn 13, Issue 5, 2011, Pages 509-517

  Nemoto, Masami ^a   Hiki, Yoshito ^b   Shimada, Kousuke ^a   Nakai, Nozomu ^b   Fujimoto, Kei ^b   Inoue, Sachiko ^c   Sakurada, Naoko ^c   Kaneko, Hideki ^c   Sugita, Masaru ^c   Okabe, Masataka ^a   Sasaki, Takashi ^a,b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GLUCOSE TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INK JET DEVICE; INSULIN TREATMENT; MALE; MASS SPECTROMETRY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; VENTILATOR;

ABSORPTION; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ARGININE; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; CELL LINE; CRESOLS; DRUG STABILITY; FLUORESCEIN-5-ISOTHIOCYANATE; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; LUNG; MALE; NEBULIZERS AND VAPORIZERS; PHARMACEUTICAL VEHICLES; RATS; RATS, WISTAR; SARCOSINE; TECHNOLOGY, PHARMACEUTICAL;

EID: 79955550014     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0114     Document Type: Article

References (27)

1. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE: Psychosocial problems and barriers to improved diabetes management: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabet Med 2005;22:1379-1385. (Pubitemid 41391315)
2. de Galan BE, Simsek S, Tack CJ, Heine RJ: Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. Neth J Med 2006;64:319-325. (Pubitemid 44614415)
3. Aidan M, Laurence EM, Peter CK, Per C: Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx ® insulin Diabetes Management System. Br J Clin Pharmacol 2005;59:546-551.
4. Kaneko M, Matsuda H: New bubble jet print head for photo-quality printing. In: NIP15: International Conference on Digital Printing Technologies. Orlando, FL: Society for Imaging Science and Technology, 1999:44-47.
5. Hisasue J, Fukuyama S, Takayama K, Izumi M, Nakagaki N, Inoue S, Kaneko H, Sakurada N, Inoue H, Nakanishi Y: Evaluation of pulmonary administration of insulin using a bubble-jet system for preparation of insulin mist [in Japanese]. J Jpn Respir Soc 2009;47:275.
6. Krauland AH, Guggi D, Bernkop-Schnürch A: Thiolated chitosan microparticles: a vehicle for nasal peptide drug delivery. Int J Pharm 2006;307:270-277. (Pubitemid 41820424)
7. Utsunomiya H, Yamakawa T, Kamei J, Kadonosono K, Tanaka S: Anti-hyperglycemic effects of plum in a rat model of obesity and type 2 diabetes, Wistar fatty rat. Biomed Res 2005;26:193-200.
8. Yamamoto A, Fujita T, Muranishi S: Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors. J Controlled Release 1996;41:57-67. (Pubitemid 26246363)
9. Morishita M, Aoki Y, Sakagami M, Nagai T, Takayama K: In situ ileal absorption of insulin in rats: effects of hyaluronidase pretreatment diminishing the mucous/glycocalyx layers. Pharm Res 2004;21:309-316. (Pubitemid 38221977)
10. Severino C, Brizzi P, Solinas A, Secchi G, Maioli M, Tonolo G: Low-dose dexamethasone in the rat: a model to study insulin resistance. Am J Physiol Endocrinol Metab 2002;283: E367-E373. (Pubitemid 34827454)
11. Bivas-Benita M, Zwier R, Junqinqer HE, Borchard G: Noninvasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 2005;61:214-218. (Pubitemid 41427629)
12. Hussain A, Majumder QH, Ahsan F: Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm Res 2006;23:138-147. (Pubitemid 43214670)
13. Lin YH, Mi FL, Chen CT, Chang WC, Penq SF, Liang HF, Sunq HW: Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 2007;8:146-152.
14. Arakawa T, Tsumoto K: Solubilization of active green fluorescent protein from insoluble particles by guanidine and arginine. Biochmen Biophys Res Commun 2003;304:148-152.
15. Sakagami M: In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58: 1030-1060. (Pubitemid 44712023)
16. Schanker LS: Drug absorption from the lung. Biochem Pharmcol 1978;27:381-385. (Pubitemid 8276840)
17. Patton JS: Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19:3-36. (Pubitemid 26167852)
18. Hussain A, Arnold JJ, Khan MA, Ahsan F: Absorption enhancers in pulmonary protein delivery. J Controlled Release 2004;94:15-24. (Pubitemid 37542374)
19. Noymer P, Schuster JA,Holst P, Rosell J,Ament B,Wilbanks T, Srinivasan S, Morishige R, Farr SJ: Efficiency and breath control without electronics. Respir Drug Deliv IX 2004;1:255-262.
20. Henry RR, Mudaliar SR, Howland WC 3rd, Chu N, Kim D, An B, Reinhardt RR: Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003;26:764-769. (Pubitemid 36929341)
21. Byron PR: Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986;75:433-439.
22. Patton JS, Bukar JG, Eldon MA: Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801. (Pubitemid 39382220)
23. Kohler D, Schlüter KJ, Kerp L, Matthys H: Nicht radioaktives Verfahren zur Messung der Lungenpermeabilität. Inhalation von Insulin. Atemw-Lungenkrkh 1987;13:230-232.
24. Sakagami M: Insulin disposition in the lung following oral inhalation in humans. A meta-analysis of its pharmacokinetics. Clin Pharmacokinet 2004;43:539-552. (Pubitemid 38858306)
25. Mudaliar S, Henry RR: Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease. Diabetes Technol Ther 2007;9(Suppl 1):S83-S92.
26. Rave K, de la Peña A, Tibaldi FS, Zhang L, Silverman B, Hausmann M, Heinemann L, Muchmore DB: AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care 2007;30:1777-1782. (Pubitemid 47036351)
27. Cryan SA: Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 2005;7:E20-E41.